
Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia
September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest
Updated on: October 11,2023
261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia
September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest
Updated on:October 11,2023
261
